UNITED STATESSECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Earliest Event Reported: December 14, 2011
PEPTIDE TECHNOLOGIES, INC.
--------------------------
(Exact name of registrant as specified in its charter)
Nevada 333-133347 98-0479983
-------------- ------------- --------------
(State or other (Commission File (IRS Employer
jurisdiction of Number) Idendification
incorporation) Number)
601 Union Street, Two Union Square, 42nd Floor, Seattle, Washington 98101
--------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(206) 388-5498
----------------
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
SECTION 1 - REGISTRANT'S BUSINESS AND OPERATIONS
Item 1.01 Entry into a Material Definitive Agreement.
On December 14, 2011, Peptide Technologies, Inc., ("the Company") agreed to
amend the Asset Purchase Agreement dated August 23, 2011.
The amended agreement stipulates that Dr. William Campbell will receive half of
one percent of all gross monies received by the company from revenue produced
from products derived from the use of all the formulae listed in the Asset
Purchase Agreement. In addition, Dr. Campbell will receive a monthly stipend of
CDN$15,000 per month, commencing from receipt of monies from the first contract
signed to purchase products derived from the use of the formulae. This agreement
is a 5 year agreement.
In consideration for these terms and remuneration, the Company will cancel all
of the 30,000,000 restricted shares issued to Dr. Campbell under the Asset
Purchase Agreement.
SECTION 5 - CORPORATE GOVERNANCE AND MANAGEMENT
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
Resignation of Director Effective December 14, 2011, William Campbell has
resigned as a director of Peptide Technologies, Inc. ("the Company"). He will
remain as Chief Scientific Officer of the Company.
SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01 Financial Statements and Exhibits
(a) Financial Statements - None.
(b) Exhibits. The following is a complete list of exhibits filed as
part of this Report. Exhibit numbers correspond to the numbers in the exhibit
table of Item 601 of Regulation S-K.
Exhibit Number Description
10.1 Form of Amendment to Asset Purchase Agreement
dated August 23, 2011
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned, hereunto duly authorized.
PEPTIDE TECHNOLOGIES, INC.
By: /s/ Debora Fortescue-Merrin
--------------------------------
Deborah Fortescue-Merrin, President
Date: December 21, 2011